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Summary
Dementia is commonly associated with 
distressing behavioural problems that warrant 
intervention. A general medical assessment 
of the patient is needed before assessing 
whether specific treatment is required. Both 
non-pharmacological and pharmacological 
interventions can be considered. The best 
available evidence is for the use of low-dose 
antipsychotic medication in patients with 
agitated or aggressive behaviour with or without 
associated psychotic symptoms. There is less 
evidence to support the use of antidepressants, 
anticonvulsants and cholinesterase inhibitors 
in patients whose dementia is complicated 
by behavioural problems. When psychotropic 
medication is prescribed to people with dementia, 
it should be regularly reviewed with a view to 
stopping it or assessing the patient after a trial  
off the medication. 
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Introduction
Dementia is a clinical syndrome usually characterised by 
progressive cognitive impairment, neuropsychiatric symptoms, 
impaired capacity to undertake activities of daily living, and 
behavioural disturbance. It affects approximately 6% of 
Australians aged 65 years and over and is the second greatest 
cause of years of life lost due to disability in Australia. More 
than 160 000 Australians suffer from dementia and many 
other family members and friends are indirectly affected. The 
commonest cause of the dementia syndrome in Australia is 
Alzheimer's disease.
Behavioural and psychological symptoms of 
dementia
A number of terms are used interchangeably to refer to the 
behavioural or psychological symptoms of dementia. These 
include neuropsychiatric symptoms of dementia, non-cognitive 
symptoms of dementia, behavioural and psychological 
symptoms of dementia and behavioural disturbance in 
dementia.
Neuropsychiatric symptoms such as apathy, anxiety, agitation, 
depression, delusions and hallucinations occur commonly in 
older people with dementia. These symptoms are a major cause 
of personal distress to patients and their families and place a 
substantial burden on the healthcare system. Neuropsychiatric 
symptoms are more important predictors of caregiver burden 
than cognitive impairment and are associated with admission 
to a nursing home. The prevalence of behavioural symptoms in 
hostel and nursing home populations is much greater than in 
older people living in the community.
The best available estimates of the prevalence of neuropsychiatric 
symptoms in an epidemiologically derived sample of older people 
with dementia living in the community come from the US Cache 
County Study.1 Across all categories of severity, 61% of patients 
had one or more neuropsychiatric symptoms and 32% had  
severe symptoms. The most prevalent individual symptoms  
were apathy (27.4%), depression (20.1%), irritability (20.4%),  
aggression/agitation (23.7%) and delusions (18.5%). 
Important assessment and management 
principles
Take a personal history from the patient and an informant 
to better understand their symptoms in the context of their 
previous experiences. Before embarking on symptomatic 
treatment for behavioural problems in people with dementia, it 
is important to assess the patient's general health. There may be 
an underlying remediable cause for the symptoms. 
Other illnesses
The development of acute agitation in people with dementia 
is often due to delirium, which is commonly precipitated by 
intercurrent illness or polypharmacy. Common causes of delirium 
include infections of the urinary tract, respiratory tract or skin, 
overzealous use of drugs with anticholinergic properties, and 
inappropriate use of hypnosedatives. Treatment should be directed 
towards the underlying cause, although short-term symptomatic 
treatment for the behavioural symptoms may be required. 
In some patients with moderate or severe dementia, the 
development of agitated behaviour may indicate unreported 
pain from conditions such as osteoarthritis. If the doctor 
suspects this possibility, a time-limited therapeutic trial of simple 
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analgesia such as regular paracetamol should be considered. 
Although case series have reported the use of narcotic 
analgesics in this situation, there is insufficient evidence to 
recommend this approach. 
In some older people with dementia, the development of a 
comorbid depressive, anxiety or psychotic disorder may present 
with abnormal behaviour. The diagnosis of such conditions in 
the presence of more than mild dementia can pose a clinical 
challenge. 
Drugs
Although drugs are often used in the management of 
behavioural problems in older people with dementia, it 
is important to review the medications they already take 
before adding more. Sometimes behavioural problems are 
caused by sub-acute delirium or other types of toxicity due 
to prescribed medication. Drugs that are particularly prone 
to cause behavioural problems in older people include those 
with anticholinergic properties (tricyclic antidepressants 
such as amitriptyline, phenothiazine antipsychotics such 
as chlorpromazine, and anti-Parkinsonian drugs such as 
benztropine), benzodiazepines such as diazepam, and narcotic 
analgesics such as tramadol. It is often possible to cease some 
medications in older people without adverse consequences. 
In residential aged-care settings a review of the patient's 
medication in consultation with a clinical pharmacist may be 
useful. 
Environment
The prudent prescriber assesses the patient's environment 
and the capacity of the patient's caregivers to cope with 
the behavioural problem. Abnormal behaviour in people 
with dementia often comes to clinical attention because of 
a mismatch between the patient, their environment and the 
characteristics of the caregivers. Sometimes a change in the 
environment or caregiver behaviour will result in substantial 
improvement in the patient's behaviour or a better match 
between the patient's needs and the capacity for those needs 
to be met. The use of psychotropic medication may then be 
unnecessary.
A change in environment may be something as straightforward 
as changing from bathing to showering, or changing from 
showering in the morning to showering in the evening, or 
changing to a different person assisting with showering. It is 
useful to place familiar objects around people with dementia in 
an attempt to make the unfamiliar seem familiar.
Impact of behaviour 
It is worth considering whether the behavioural disturbance 
is causing the patient obvious distress or making it difficult 
for others to care for them. If there is no underlying reversible 
cause and the behaviour is not particularly problematic, it might 
be worth considering a further period of observation without 
treatment. Hallucinations are one example of a symptom that 
does not always warrant treatment. The routine prescription of 
psychotropic medication in the absence of good general care of 
patients with dementia is likely to lead to further agitation and 
complications like confusion and falls. 
Non-pharmacological approaches
A wide range of non-pharmacological interventions has been 
tested in behaviourally disturbed people with dementia. Many 
of the trials have had significant methodological limitations. 
Nevertheless, a recent systematic review found that there was 
evidence to support the efficacy of activity programs, music, 
behaviour therapy, light therapy, carer education and changes 
to the physical environment.2 In well-run residential aged-care 
facilities some of these techniques are in routine use.
Interventions for patients with dementia and behavioural 
problems should be individualised. Specific discussion of this 
complex issue is contained in a report to the Commonwealth 
Department of Health and Ageing on the psychosocial 
approaches to challenging behaviour in dementia.3 
Pharmacological approaches
When non-pharmacological approaches are insufficient to 
manage the patient's behaviour, drugs can be added to their 
treatment. It is important to consider the likely benefits against 
the likelihood of adverse effects and drug interactions.
Antipsychotics 
There is some evidence for the efficacy of both typical (e.g. 
haloperidol) and atypical (e.g. risperidone4, olanzapine5) 
antipsychotic drugs in the treatment of psychotic symptoms in 
people with dementia. There is also some evidence for the use 
of these drugs in people with dementia who are aggressive or 
agitated but who do not have overt psychotic symptoms. 
Although the so-called atypical antipsychotic medications 
(risperidone, olanzapine, quetiapine, amisulpride, aripiprazole) 
have safer adverse effect profiles than typical antipsychotic 
medications, most of them are not subsidised by the 
Pharmaceutical Benefits Scheme (PBS) for people with 
dementia in the absence of schizophrenia. The best evidence 
is for low-dose risperidone, which has been approved for the 
management of behavioural disturbance in dementia. The usual 
starting dose of risperidone in older people with dementia is 
0.25–0.5 mg daily, with the final dose generally 1–2 mg per day. 
A Cochrane review found that haloperidol was useful for 
aggression, but not for other aspects of agitation in people with 
dementia.6 If haloperidol is to be used in the treatment of either 
psychotic symptoms or agitation/aggression, it is important 
to use the lowest effective dose. The usual starting dose of 
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haloperidol in older people is 0.5 mg daily, with the final daily 
dose generally 1–2 mg per day. 
If either haloperidol or an atypical antipsychotic drug is used, 
it is important to titrate the dose slowly and check the patient 
frequently for adverse effects. The most important adverse 
effects in older patients are Parkinsonism, confusion and 
postural hypotension. Parkinsonism can develop after several 
weeks of treatment and may present with falls. At these doses, 
akathisia is a much less frequent problem than when higher 
doses are used.
When starting an antipsychotic drug in older people with 
dementia, it is important to have a stopping rule. Prescribe 
treatment for no longer than 3–6 months before tapering 
the dose and undertaking a trial of ceasing the medication. 
Patients should be regularly reviewed because their behavioural 
problems may abate as their dementia progresses.
Recently, concern has arisen about an increased risk of 
cerebrovascular adverse effects when risperidone or olanzapine 
are used to treat psychotic or behavioural symptoms in older 
patients with dementia. Although no prospective studies have 
been designed specifically to examine this outcome, pooled 
secondary analyses of randomised controlled trials suggest 
that both drugs are associated with a small but significantly 
increased risk of cerebrovascular adverse effects.7,8 In contrast, a 
retrospective cohort study did not find a statistically significant 
increased risk of stroke when risperidone and olanzapine were 
compared with conventional antipsychotic medications in 
older people with mixed diagnoses.9 It is not known whether 
haloperidol, quetiapine, amisulpride or aripiprazole are also 
associated with cerebrovascular adverse effects. Nor is it known 
whether the observed increased risk of cerebrovascular adverse 
effects also affects older patients with psychotic disorders but no 
dementia. It is therefore important to recognise that there is an 
increased risk in prescribing antipsychotics in these situations, 
so the harms and benefits should be clearly identified and 
discussed in as much detail as possible with the patient and 
their carers.
Antidepressants 
Depression and anxiety symptoms occur commonly in people 
with dementia. Sometimes these symptoms are short-lived and 
do not require specific treatment. However, if the person with 
dementia develops a clinically significant depressive or anxiety 
disorder they should be treated.
Modern antidepressant medication is effective against both 
depressive and anxiety disorders, although the evidence base 
in patients with dementia is weak. The adverse effect profiles 
of sertraline, citalopram, escitalopram and moclobemide make 
them suitable for use in older people, including those with 
dementia. Evidence is best for sertraline, for which the usual 
starting dose in this patient group is 25 mg daily.10 Treatment, 
if effective, should usually continue for about 12 months, or 
longer if there is a history of recurrent depression.
There is a risk of hyponatraemia with antidepressants in older 
people.11 The prescriber should check the patient's serum 
sodium before and approximately one week after starting 
treatment with an antidepressant. However, hyponatraemia can 
occur several weeks into therapy, so a high index of suspicion 
should be maintained. Increasing confusion is a common 
symptom of hyponatraemia in older patients. Hyponatraemia 
seems to be more common in women, in patients with 
cerebrovascular disease, and in patients on diuretics.
Anticonvulsants 
Carbamazepine and sodium valproate have been used in the 
management of agitated behaviour in people with dementia. 
The evidence base is rather weak for both drugs, although does 
tend to favour carbamazepine12, despite its relatively greater 
propensity for adverse effects, including drug-drug interactions. 
Like antipsychotic treatment, anticonvulsants should only be 
prescribed for a limited time.
Cholinesterase inhibitors 
There are preliminary data showing that some patients 
with dementia-related behavioural disturbance benefit from 
treatment with cholinesterase inhibitors. These data are 
based mainly on subsidiary analyses of studies designed for 
other purposes. Prescribers should be aware, however, that 
cholinesterase inhibitor treatment is sometimes associated 
with deterioration in behaviour. Also, there are no independent 
head-to-head studies comparing donepezil, rivastigmine and 
galantamine in the treatment of neuropsychiatric or behavioural 
symptoms in dementia.
Benzodiazepines 
Benzodiazepines should be avoided in older people with 
dementia. Benzodiazepines impair cognition (particularly 
memory), gait (leading to falls) and, like all sedatives, may 
also worsen the common clinical problem of constipation. If a 
benzodiazepine is prescribed for severe anxiety, it should not 
be continued for more than two weeks. Benzodiazepines should 
not be used to treat insomnia in people with dementia.
Management of aggression
Physical aggression is common in dementia, particularly 
towards caregivers. Sometimes aggression can be managed 
by modifying the behaviour of the caregiver or by modifying 
the environment in some other way. However, pharmacological 
intervention is often required, particularly when there is a risk of 
physical injury to the patient or their carer.
In an emergency, aggressive behaviour in a patient with 
dementia may need to be treated with antipsychotic medication. 
If oral treatment is feasible, risperidone or haloperidol should 
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be tried. If parenteral treatment is required, the short-term use 
of intramuscular haloperidol or olanzapine is often appropriate. 
It is particularly important that following the administration of 
parenteral antipsychotic medication, the patient with dementia 
is monitored for an extended period. Adverse effects including 
excessive sedation and extrapyramidal reactions may occur.
The dose of antipsychotic medication should vary according 
to the size, gender, age and general condition of the patient. 
Intramuscular haloperidol is often administered in an initial dose 
of 1–2 mg and intramuscular olanzapine in an initial dose of  
2.5 mg. Repeated dosing is sometimes required, but increases 
the risk of adverse effects.
Although approved for behavioural problems, intramuscular 
olanzapine is not currently subsidised by the PBS. Droperidol 
and midazolam are not recommended for use in older people 
with dementia. A combination of parenteral benzodiazepines 
with parenteral antipsychotic medication can lead to excessive 
sedation in older people and is not recommended for routine 
use.
If physical aggression is more chronic in nature and associated 
with other agitated behaviour, a trial of anticonvulsant 
medication, either sodium valproate or carbamazepine, is often 
appropriate. In this situation, these anticonvulsants may be used 
as antipsychotic sparing medications.
Ethical considerations
In most jurisdictions treatment without consent has been dealt 
with by statute law and a list of substitute decision makers is 
specified. In certain circumstances referral to a guardianship 
board (or similar local body) may be prudent, or even required, 
before treatment without consent can proceed.
In emergencies, particularly where physical violence to self or 
others is concerned, the doctor's duty of care might override the 
requirement of informed consent. Although not yet universal, 
in some jurisdictions patients with dementia are covered by the 
local Mental Health Act.
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Self-test questions
The following statements are either true or false  
(see answers on page 79)
5. Altered behaviour in a patient with dementia may be the 
result of an intercurrent illness.
6. If an antipsychotic drug is prescribed to control behaviour 
problems in a patient with dementia, its use should be 
reviewed as the dementing condition changes.
